If the average price target of $11.00 set by distinguished experts for Atai Life Sciences N.V. over the past few weeks is reached this year, there would be a potential upside of approximately 436.59% from the last closing price in May, 2024. This potential increase is based on a high estimate of $21.00 and a low estimate of $6.00.

$11.00

436.59% Upside

Buy

Atai Life Sciences N.V. Fair Value Forecast for 2023 - 2025 - 2030

Atai Life Sciences N.V.'s Price has seen growth In the last three years, going from $0.00 to $0.00 – a gain of 100.00% In the next year, analysts believe that Fair Value will reach $0.00 – an increase of 100.00%. For the next six years, the forecast is forFair Value to grow by 100.00%.

2025 Fair Value Forecast

$0.00

2026 Fair Value Forecast

$0.00

2027 Fair Value Forecast

$0.00

2028 Fair Value Forecast

$0.00

2029 Fair Value Forecast

$0.00

2030 Fair Value Forecast

$0.00

Atai Life Sciences N.V. Revenue Forecast for 2023 - 2025 - 2030

Atai Life Sciences N.V.'s Revenue has decreased by 98.87% In the last year, from $20.38M to $230.00k. In the next year, analysts believe that Revenue will reach $20.38M – an increase of 8760.87%. For the next eight years, the forecast is forRevenue to grow by 32890229.41%.

2023 Rev Forecast

$0.02B

2024 Rev Forecast

$0.60B

2025 Rev Forecast

$17.79B

2026 Rev Forecast

$0.47B

2027 Rev Forecast

$5.94B

2028 Rev Forecast

$75.53B

2029 Rev Forecast

$961.22B

2030 Rev Forecast

$75.65B

Atai Life Sciences N.V. Dividend per Share Forecast for 2023 - 2025 - 2030

Atai Life Sciences N.V. Free Cash Flow Forecast for 2023 - 2025 - 2030

Atai Life Sciences N.V. EBITDA Forecast for 2023 - 2025 - 2030

In the last two years, Atai Life Sciences N.V.'s EBITDA has increased by 56.60%, going from $-92.12M to $-144.26M. For the next year, 0 analysts project Atai Life Sciences N.V.'s EBITDA to drop by 18.88%, reaching $-117.02M. By 2030, professionals believe that Atai Life Sciences N.V.'s EBITDA will decrease by 16.94%, reaching $-119.83M – a concerning trend for the company.

2023 EBITDA Forecast

$-117018903.33

2024 EBITDA Forecast

$-110485347.90

2025 EBITDA Forecast

$-115114683.97

2026 EBITDA Forecast

$-124772805.96

2027 EBITDA Forecast

$-122339736.24

2028 EBITDA Forecast

$-118355538.83

2029 EBITDA Forecast

$-117416584.89

2030 EBITDA Forecast

$-119827538.77

Atai Life Sciences N.V. EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Atai Life Sciences N.V.'s EBIT has grown, increasing from $-92.14M to $-144.43M – an increase of 56.75%. According to 0 prominent analysts, Atai Life Sciences N.V.'s EBIT will fall by 18.94% in the next year, reaching $-117.08M. By 2030, professionals believe that Atai Life Sciences N.V.'s EBIT will decrease by 16.98%, reaching $-119.91M – a concerning trend for the company.

2023 EBIT Forecast

$-117079772.33

2024 EBIT Forecast

$-110538915.72

2025 EBIT Forecast

$-115177865.55

2026 EBIT Forecast

$-124872002.57

2027 EBIT Forecast

$-122428673.72

2028 EBIT Forecast

$-118433418.00

2029 EBIT Forecast

$-117489898.43

2030 EBIT Forecast

$-119906274.01

Atai Life Sciences N.V. EPS Price Prediction Forecast for 2023 - 2025 - 2030

Atai Life Sciences N.V.'s EPS has seen growth In the last three years, going from $-1.21 to $0.00 – a gain of 100.00% In the next year, analysts believe that EPS will reach $0.00 – an increase of 100.00%. For the next six years, the forecast is forEPS to grow by 100.00%.

2025 EPS Forecast

$0.00

2026 EPS Forecast

$0.00

2027 EPS Forecast

$0.00

2028 EPS Forecast

$0.00

2029 EPS Forecast

$0.00

2030 EPS Forecast

$0.00